Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specifications. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
November 18, 2004
Date of Patent:
October 6, 2009
Assignee:
Array Biopharma Inc.
Inventors:
Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
Abstract: Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
Type:
Application
Filed:
January 24, 2007
Publication date:
October 1, 2009
Applicant:
ARRAY BIOPHARMA INC.
Inventors:
Thomas D. Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Rustam Ferdinand Garrey, Ronald Jay Hinklin, Ajay Singh, Timothy M. Turner
Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Type:
Application
Filed:
March 26, 2009
Publication date:
October 1, 2009
Applicants:
AstraZeneca AB, Array Biopharma, Inc.
Inventors:
Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
Abstract: This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Type:
Grant
Filed:
April 21, 2008
Date of Patent:
September 8, 2009
Assignee:
Array BioPharma Inc.
Inventors:
Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
Abstract: Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases and inflammatory conditions in mammals and pharmaceutical compositions containing such compounds.
Type:
Application
Filed:
August 5, 2008
Publication date:
August 27, 2009
Applicant:
Array BioPharma Inc.
Inventors:
Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
Abstract: The present invention provides N-3?-pyridyl-methyl or N-2?-pyrazinylmethyl thiazolium derivatives of formula (I) which are useful as transketolase inhibitors wherein R1, R2, R3, Y, R5-R9, Ra-Rd, n and X? are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for inhibiting transketolase activity, reducing cellular ribose-5-phosphate levels, inhibiting nucleic acid synthesis, inhibiting cell proliferation and tumor cell growth in vitro and in vivo, stimulating apoptosis in tumor cells and treating cancer by administering a compound of formula (I) or a pharmaceutical composition thereof.
Type:
Application
Filed:
March 23, 2005
Publication date:
August 20, 2009
Applicant:
ARRAY BIOPHARMA INC.
Inventors:
Steven A. Boyd, Kevin R. Condroski, Jason De Meese, Stephen S. Gonzales, Indrani W. Gunawardana, Tomas Kaplan, Yvan Le Huerou, Joseph Lyssikatos, Todd T. Romoff, Francis X. Sullivan, Allen Thomas
Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and W are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative and inflammatory diseases in mammals and pharmaceutical compositions containing such compounds.
Type:
Application
Filed:
August 5, 2008
Publication date:
August 20, 2009
Applicant:
Array BioPharma Inc.
Inventors:
Allison L. Marlow, Eli Wallance, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
March 18, 2008
Date of Patent:
August 18, 2009
Assignee:
Array BioPharma Inc.
Inventors:
Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
November 18, 2004
Date of Patent:
August 18, 2009
Assignee:
Array BioPharma Inc.
Inventors:
Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, T. Brian Hurley, Allison L. Marlow, James Blake
Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Type:
Grant
Filed:
May 18, 2006
Date of Patent:
July 28, 2009
Assignee:
Array Biopharma Inc.
Inventors:
Ellen Laird, George Topalov, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse
Abstract: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Type:
Application
Filed:
April 18, 2008
Publication date:
July 2, 2009
Applicants:
InterMune, Inc., Array BioPharma, Inc.
Inventors:
Lawrence M Blatt, Scott D. Seiwert, Steven W. Andrews, Pierre Martin, Andreas Schumacher, Bradley Barnett, C. Todd Eary, Robert Kaus, Timothy Kercher, Weidong Liu, Michael Lyon, Paul Nichols, Bin Wang, Tarek Sammakia, April Kennedy, Yutong Jiang
Abstract: Disclosed are compounds of the Formula I and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein. Such compounds are useful in the treatment of immunoregulatory and respiratory diseases in mammals. Also disclosed are methods of using such compounds in the treatment of immunoregulatory and respiratory diseases in mammals and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
January 19, 2006
Date of Patent:
June 30, 2009
Assignee:
Array Biopharma Inc.
Inventors:
Stephen T. Schlacter, John J. Gaudino, Laurence E. Burgess, Kevin W. Hunt
Abstract: Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
Type:
Application
Filed:
March 23, 2007
Publication date:
June 18, 2009
Applicant:
Array BioPharma Inc.
Inventors:
Thomas D. Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Ronald Jay Hinklin, Ajay Singh
Abstract: The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Type:
Application
Filed:
July 17, 2006
Publication date:
June 11, 2009
Applicants:
Intermune, Inc., Array Biopharma Inc.
Inventors:
Lawrence M. Blatt, Scott D. Seiwert, Steven W. Andrews, Pierre Martin, Andreas Schumacher, Bradley Barnett, C. Todd Eary, Robert Kaus, Timothy Kercher, Weidong Liu, Michael Lyon, Paul Nichols, Bin Wang, Tarek Sammakia, April Kennedy, Yutong Jiang
Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
Type:
Application
Filed:
February 2, 2009
Publication date:
June 11, 2009
Applicant:
ARRAY BIOPHARMA INC.
Inventors:
Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
Abstract: Disclosed are compounds of the Formulas III and IV and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
Type:
Application
Filed:
January 20, 2009
Publication date:
June 4, 2009
Applicant:
ARRAY BIOPHARMA INC.
Inventors:
James F. Blake, Joseph P. Lyssikatos, Hong-Woon Yang, Eli M. Wallace
Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
Type:
Application
Filed:
January 20, 2009
Publication date:
June 4, 2009
Applicant:
ARRAY BIOPHARMA INC.
Inventors:
James F. Blake, Joseph P. Lyssikatos, Hong-Woon Yang, Eli M. Wallace, Jeongbeob Seo
Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
Type:
Application
Filed:
February 2, 2009
Publication date:
June 4, 2009
Applicant:
ARRAY BIOPHARMA INC.
Inventors:
Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
Type:
Application
Filed:
February 2, 2009
Publication date:
May 28, 2009
Applicant:
Array BioPharma Inc.
Inventors:
Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey